Skip to main navigation Skip to search Skip to main content

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

Kelli L. Kuhen, Arnab K. Chatterjee, Matthias Rottmann, Kerstin Gagaring, Rachel Borboa, Jennifer Buenviaje, Zhong Chen, Carolyn Francek, Tao Wu, Advait Nagle, S. Whitney Barnes, David Plouffe, Marcus C.S. Lee, David A. Fidock, Wouter Graumans, Marga Van De Vegte-Bolmer, Geert J. Van Gemert, Grennady Wirjanata, Boni Sebayang, Jutta MarfurtBruce Russell, Rossarin Suwanarusk, Ric N. Price, Francois Nosten, Anchalee Tungtaeng, Montip Gettayacamin, Jetsumon Sattabongkot, Jennifer Taylor, John R. Walker, David Tully, Kailash P. Patra, Erika L. Flannery, Joseph M. Vinetz, Laurent Renia, Robert W. Sauerwein, Elizabeth A. Winzeler, Richard J. Glynne, Thierry T. Diagana

Research output: Contribution to journalArticlepeer-review

161 Downloads (Pure)

Fingerprint

Dive into the research topics of 'KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology